Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
Dramatic Dominance d: A Survey of \Feelings in front of an audience\ Theater Play - 2Selena Quintanilla documentary 'Selena y Los Dinos: A Family's Legacy' is coming to Netflix
- 3The Electric Toyota Hilux Is Finally here, But It's Not Cheap
- 4Find Unexpected, yet invaluable treasure Excursion Rentals
- 5PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds
- Where should we send a real 'Hail Mary' spacecraft? A new study has the answers
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- Eight Muslim nations condemn Israel's 'dangerous' new death penalty law
- Fears of global aluminum shortages intensify
- Without evidence, CDC changes messaging on vaccines and autism
- Share your number one city visit transport that leaves a mark on the world wake up!
- Figure out How to Ascertain the Restitution Time frame for Your Sunlight based chargers
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- US FDA approves Kura-Kyowa's blood cancer therapy
